Cytosorbents Consensus Price Target Increased by 1,900% to $48.45
The average one-year price target for Cytosorbents (NASDAQCM:CTSO) has been revised to $48.45 / share. This is an increase of 1,900.00% from the prior estimate of $2.42 dated August 25, 2026. These figures represent aggregate analyst targets collected by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $15.15 to a high of $84.00 / share. The average price target represents an increase of 698.20% from the latest reported closing price of $6.07 / share as of September 14, 2026.
Looking at the historical target trajectory, the mean target was $48.45 on September 15, 2026, compared to $2.42 on August 28, 2026, and $2.93 on August 4, 2026. The observed twelve-month high mean of $48.45 was recorded on September 15, 2026, while the observed twelve-month low mean of $2.42 was recorded on August 28, 2026. This represents a target change of +1,552.17% since the 90-day baseline date of June 8, 2026.
For context, the company's stock price experienced a one-week change of +1,633.76% from a baseline close of $0.35 on September 4, 2026, and a one-month change of +1,417.85% from a baseline close of $0.40 on August 14, 2026. In its latest earnings report on August 6, 2026, Cytosorbents reported an actual EPS of -0.07, compared to an estimated EPS of -0.0459. The company's actual revenue was $9,633,000.00, representing a +1.05% surprise against the estimated revenue of $9,532,920.00.
Cytosorbents Corporation, based in the United States, operates within the biotechnology sector, primarily focusing on critical care immunotherapy products. Its flagship product, CytoSorb, is a blood purification technology aimed at reducing excessive immune responses. Under the GICS classification, the company is categorized in the Financials sector, Capital Markets industry, and Specialized Finance sub-industry. Within this sub-industry, 27 companies are covered, with 13 experiencing target raises, 4 lowered, and 10 remaining unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +30.62%.
As of the September 1, 2026 recommendation period, the analyst recommendation trend showed 3 hold ratings, 1 sell rating, and 2 strong sell ratings, representing a total of 6 recommendations. This distribution remained unchanged from the August 1, 2026 period.
In comparison, peer companies in the blood purification and medical device space showed varying target revisions and implied changes. While peer target revisions showed mixed directions, all three peers maintained positive implied changes.
| Company name | Target revision | Implied change |
|---|---|---|
| Aethlon Medical | -50.00% | +233.33% |
| Cerus | +9.82% | +103.40% |
| ICU Medical | +10.85% | +26.56% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.